Craig Hallum Increases Cellebrite DI (NASDAQ:CLBT) Price Target to $23.00

Cellebrite DI (NASDAQ:CLBT) had its price objective hoisted by Craig Hallum from $20.00 to $23.00 in a report issued on Wednesday, Benzinga reports. They currently have a buy rating on the stock.

A number of other brokerages have also recently issued reports on CLBT. Needham & Company LLC lifted their price target on shares of Cellebrite DI from $14.00 to $17.00 and gave the company a buy rating in a research report on Friday, August 16th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Cellebrite DI from $15.00 to $18.00 and gave the company a buy rating in a report on Friday, August 16th. JPMorgan Chase & Co. raised their price objective on Cellebrite DI from $14.00 to $15.00 and gave the company an overweight rating in a research report on Wednesday, August 14th. Lake Street Capital boosted their target price on Cellebrite DI from $13.50 to $17.00 and gave the stock a buy rating in a report on Friday, August 16th. Finally, Bank of America raised their price target on Cellebrite DI from $13.00 to $17.00 and gave the company a buy rating in a report on Friday, August 16th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Cellebrite DI currently has an average rating of Buy and an average price target of $18.57.

Cellebrite DI Trading Down 2.1 %

NASDAQ:CLBT opened at $16.85 on Wednesday. The company has a 50-day moving average price of $15.61 and a 200-day moving average price of $12.85. The stock has a market cap of $3.47 billion, a price-to-earnings ratio of -29.05, a P/E/G ratio of 2.32 and a beta of 1.52. Cellebrite DI has a 12 month low of $6.36 and a 12 month high of $17.82.

Cellebrite DI (NASDAQ:CLBT) last posted its earnings results on Thursday, August 15th. The company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.02. The firm had revenue of $95.70 million for the quarter, compared to the consensus estimate of $91.94 million. Cellebrite DI had a positive return on equity of 5,902.06% and a negative net margin of 28.51%. The business’s revenue for the quarter was up 24.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.05 EPS. Equities analysts forecast that Cellebrite DI will post 0.31 EPS for the current fiscal year.

Institutional Trading of Cellebrite DI

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. lifted its holdings in Cellebrite DI by 59.6% during the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company’s stock valued at $33,000 after purchasing an additional 1,017 shares in the last quarter. Scalar Gauge Management LLC lifted its stake in shares of Cellebrite DI by 15.2% during the 2nd quarter. Scalar Gauge Management LLC now owns 453,554 shares of the company’s stock valued at $5,420,000 after buying an additional 60,000 shares in the last quarter. Apis Capital Advisors LLC lifted its stake in shares of Cellebrite DI by 22.3% during the 2nd quarter. Apis Capital Advisors LLC now owns 274,000 shares of the company’s stock valued at $3,274,000 after buying an additional 50,000 shares in the last quarter. Magnetar Financial LLC bought a new position in Cellebrite DI in the 2nd quarter worth $143,000. Finally, Sei Investments Co. increased its stake in Cellebrite DI by 16.9% in the 2nd quarter. Sei Investments Co. now owns 141,644 shares of the company’s stock worth $1,693,000 after buying an additional 20,478 shares in the last quarter. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.